Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
暂无分享,去创建一个
Kshitij Srivastava | E. Besemfelder | Markus Thomas | H. Augustin | M. Pasparakis | M. Jugold | C. Korn | Junhao Hu | M. Teichert | S. Kapel | Soniya Savant
[1] I. Keklikoglou,et al. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. , 2014, Cell reports.
[2] C. Borg,et al. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels , 2013, BMC Cancer.
[3] Y. Kienast,et al. Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy , 2013, Clinical Cancer Research.
[4] M. Parmar,et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. , 2013, The Lancet. Oncology.
[5] H. Augustin,et al. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. , 2013, Cancer research.
[6] Y. Kienast,et al. A Novel Angiopoietin-2 Selective Fully Human Antibody with Potent Anti-Tumoral and Anti-Angiogenic Efficacy and Superior Side Effect Profile Compared to Pan-Angiopoietin-1/-2 Inhibitors , 2013, PloS one.
[7] J. Hecht,et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. , 2012, The Lancet. Oncology.
[8] T. Gruenberger,et al. Intermediate Monocytes but Not TIE2-Expressing Monocytes Are a Sensitive Diagnostic Indicator for Colorectal Cancer , 2012, PloS one.
[9] A. Nagy,et al. CCR2 recruits an inflammatory macrophage subpopulation critical for angiogenesis in tissue repair. , 2012, Blood.
[10] M. Felcht,et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. , 2012, The Journal of clinical investigation.
[11] G. Zhuang,et al. Induction of Bv8 Expression by Granulocyte Colony-stimulating Factor in CD11b+Gr1+ Cells , 2012, The Journal of Biological Chemistry.
[12] A. Shimabukuro-Vornhagen,et al. Analysis of Tie2-Expressing Monocytes (TEM) in Patients With Colorectal Cancer , 2012, Cancer investigation.
[13] K. Alitalo,et al. Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis , 2012, Journal of the National Cancer Institute.
[14] H. Okada,et al. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy , 2011, Journal of Neuro-Oncology.
[15] Jinghang Zhang,et al. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.
[16] L. Naldini,et al. Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis , 2011, Clinical Cancer Research.
[17] P. Carmeliet,et al. Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.
[18] L. Naldini,et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.
[19] Janet Do,et al. Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth , 2011, Clinical Cancer Research.
[20] K. Medina,et al. Adult hematopoietic stem cells require NKAP for maintenance and survival. , 2010, Blood.
[21] H. Augustin,et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy , 2010, British Journal of Cancer.
[22] D. Nam,et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. , 2010, Cancer cell.
[23] M. Bouvet,et al. Metronomic Gemcitabine in Combination with Sunitinib Inhibits Multisite Metastasis and Increases Survival in an Orthotopic Model of Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.
[24] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[25] D. Schadendorf,et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma , 2010, The Journal of Experimental Medicine.
[26] D. McDonald,et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. , 2010, Cancer research.
[27] A. Lusis,et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. , 2010, Blood.
[28] Xin Lu,et al. Chemokine (C-C Motif) Ligand 2 Engages CCR2+ Stromal Cells of Monocytic Origin to Promote Breast Cancer Metastasis to Lung and Bone* , 2009, The Journal of Biological Chemistry.
[29] Y. Meng,et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models , 2009, Proceedings of the National Academy of Sciences.
[30] J. Pollard,et al. Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.
[31] John M L Ebos,et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.
[32] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[33] Gavin Thurston,et al. Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.
[34] S. Karumanchi,et al. Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium , 2009, Molecular and Cellular Biology.
[35] M Baum,et al. The effects of surgery on tumor growth: a century of investigations. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] A. Goldhirsch,et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Hua Yu,et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. , 2008, The Journal of clinical investigation.
[38] F. Peale,et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis , 2007, Nature.
[39] M. Humbert,et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. , 2007, American journal of respiratory and critical care medicine.
[40] G. Fuh,et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.
[41] P. Lin,et al. Endothelial cell adhesion molecules and cancer progression. , 2007, Current medicinal chemistry.
[42] R. Kerbel,et al. Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel , 2006, Clinical Cancer Research.
[43] G. Lip,et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. , 2006, Neoplasia.
[44] F. Peale,et al. Cross-species Vascular Endothelial Growth Factor (VEGF)-blocking Antibodies Completely Inhibit the Growth of Human Tumor Xenografts and Measure the Contribution of Stromal VEGF* , 2006, Journal of Biological Chemistry.
[45] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[46] L. Kaiser,et al. Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.
[47] P. Hall,et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[48] K. Sayama,et al. Nuclear Translocation of Phosphorylated STAT3 Is Essential for Vascular Endothelial Growth Factor-induced Human Dermal Microvascular Endothelial Cell Migration and Tube Formation* , 2003, Journal of Biological Chemistry.
[49] J. Turkson,et al. Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.
[50] G. Yancopoulos,et al. In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis , 1999, Experimental Neurology.
[51] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.
[52] C. Pace,et al. How to measure and predict the molar absorption coefficient of a protein , 1995, Protein science : a publication of the Protein Society.
[53] Alastair H Kyle,et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. , 2013, Cancer research.
[54] N. Petrelli,et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] S. Groshen,et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] C. Ni,et al. ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. , 2005, Journal of biomedical science.